Cardiovascular disease is the number one cause of death and hospitalization throughout the Western World. Reperfusion therapy with fibrinolytic agents has significantly reduced early mortality from acute myocardial infarction and disability from stroke. Despite efforts to enhance the fibrin specificity of genetically engineered fibrinolytic agents, significan bleeding risks have prompted the development of alternative pharmacologic and device approaches for reperfusion. We propose a targeted drug delivery system to improve efficacy and safety. We will engineer a tissue-targeted, filamentous platform technology to deliver inhibitors of plasminogen activator inhibitor-1 (PAI-1). Tissue-specific inhibition of PAI-1 is expected to reduce thrombus burden and vessel reocclusion, while minimizing adverse effects (hemorrhage), and thus improve net clinical benefit. The filamentous structure of the drug carrier has favorable flow dynamics promoting vessel wall and thrombus accumulation, thereby enhancing local endogenous fibrinolysis with reduced bleeding risk. This technology is expected to yield a formulation with high thrombus-specificity and efficacy that will outperform systemic antibody- or small molecule inhibitor-based therapies. A combination of in vitro and in vivo assays will be performed to gain insights into the dynamics of clot-specificity, drug release, efficacy, and potential bleeding risk. A combination of in vivo intravital microscopy, ex vivo imaging, and quantitative tissue analysis will provide detailed information on the efficiency of targeting nanoparticles and PAI-1 inhibitors to the thrombus. We will address whether the nanotherapy improves localized treatment by promoting endogenous fibrinolysis secondary to PAI-1 inhibition and thereby limiting thrombus burden. We will examine the effect of nanotherapy versus free drugs on thrombus growth/stability and carotid artery occlusion time. The effect of PAI-1 inhibition on hemostasis (i.e. tail bleeding time) and blood loss will be assessed. This approach represents a radical shift from current targeting strategies. Nanomedicines targeting the vessel wall could have a significant clinical impact in atherothrombosis, venous thromboembolism, restenosis, and transplant vasculopathy.

Public Health Relevance

Cardiovascular disease is the number one cause of death and hospitalization. Reperfusion therapy with fibrinolytic agents has significantly reduced early mortality from acute myocardial infarction and disability from stroke. Nevertheless, fibrinolytic agents bear a high risk of bleeding complications and death. We propose a drug delivery system to deliver fibrinolytic therapies in a tissue-specific manner to the injured vessel wall, therefore increasing therapy success while minimizing adverse effects, leading to an improved net clinical benefit.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Exploratory/Developmental Grants (R21)
Project #
5R21HL121130-02
Application #
8965514
Study Section
Gene and Drug Delivery Systems Study Section (GDD)
Program Officer
Danthi, Narasimhan
Project Start
2014-11-14
Project End
2017-10-31
Budget Start
2015-11-01
Budget End
2017-10-31
Support Year
2
Fiscal Year
2016
Total Cost
Indirect Cost
Name
Case Western Reserve University
Department
Radiation-Diagnostic/Oncology
Type
Schools of Medicine
DUNS #
077758407
City
Cleveland
State
OH
Country
United States
Zip Code
44106
Pitek, Andrzej S; Veliz, Frank A; Jameson, Slater A et al. (2018) Interactions Between Plant Viral Nanoparticles (VNPs) and Blood Plasma Proteins, and Their Impact on the VNP In Vivo Fates. Methods Mol Biol 1776:591-608
Lee, Parker W; Isarov, Sergey A; Wallat, Jaqueline D et al. (2017) Polymer Structure and Conformation Alter the Antigenicity of Virus-like Particle-Polymer Conjugates. J Am Chem Soc 139:3312-3315
Pitek, Andrzej S; Wang, Yunmei; Gulati, Sahil et al. (2017) Elongated Plant Virus-Based Nanoparticles for Enhanced Delivery of Thrombolytic Therapies. Mol Pharm 14:3815-3823
Pitek, Andrzej S; Wen, Amy M; Shukla, Sourabh et al. (2016) The Protein Corona of Plant Virus Nanoparticles Influences their Dispersion Properties, Cellular Interactions, and In Vivo Fates. Small 12:1758-69
Ganguly, Rituparna; Wen, Amy M; Myer, Ashley B et al. (2016) Anti-atherogenic effect of trivalent chromium-loaded CPMV nanoparticles in human aortic smooth muscle cells under hyperglycemic conditions in vitro. Nanoscale 8:6542-54
Wen, Amy M; Steinmetz, Nicole F (2016) Design of virus-based nanomaterials for medicine, biotechnology, and energy. Chem Soc Rev 45:4074-126
Pitek, Andrzej S; Jameson, Slater A; Veliz, Frank A et al. (2016) Serum albumin 'camouflage' of plant virus based nanoparticles prevents their antibody recognition and enhances pharmacokinetics. Biomaterials 89:89-97
Koudelka, Kristopher J; Pitek, Andrzej S; Manchester, Marianne et al. (2015) Virus-Based Nanoparticles as Versatile Nanomachines. Annu Rev Virol 2:379-401
Bruckman, Michael A; Randolph, Lauren N; Gulati, Neetu M et al. (2015) Silica-coated Gd(DOTA)-loaded protein nanoparticles enable magnetic resonance imaging of macrophages. J Mater Chem B 3:7503-7510
Shukla, Sourabh; Steinmetz, Nicole F (2015) Virus-based nanomaterials as positron emission tomography and magnetic resonance contrast agents: from technology development to translational medicine. Wiley Interdiscip Rev Nanomed Nanobiotechnol 7:708-21

Showing the most recent 10 out of 11 publications